Diabetes Drug Empagliflozin Lowered Inflammatory Markers
A small study found the medication reduced inflammatory markers linked to heart disease risk in adults with prediabetes.
Updated on Oct. 13, 2026 in Diabetes
Live Poll
Should medical research prioritize finding new uses for existing drugs to help treat chronic health conditions?
Researchers at Vanderbilt Health found that the drug empagliflozin reduced monocyte-platelet aggregates in individuals with obesity and prediabetes. These findings suggest the medication may have protective effects beyond glycemic control.
Why it matters
This research explores how SGLT2 inhibitors might lower obesity-associated inflammation and reduce heart disease risk. Understanding these mechanisms is crucial for managing the long-term health complications associated with prediabetes and obesity.
In a 3-month pilot study of 16 women with obesity and prediabetes, researchers observed that empagliflozin treatment reduced monocyte-platelet aggregates compared to a low-calorie diet group. These results are preliminary and require validation in larger trials.
The players
Vanderbilt Health
A prominent medical research center and healthcare provider based in Nashville that manages complex metabolic conditions.
The details
Empagliflozin belongs to a class of drugs known as SGLT2 inhibitors. Beyond managing blood sugar, the researchers found the drug induced metabolic reprogramming of circulating monocytes toward a more stable phenotype. By using genetic sequencing and cellular imaging, the team documented that these cellular changes directly correlated with fewer monocyte-platelet aggregates, which are inflammatory markers often associated with vascular damage.
Timeline
Two weeks: Initial reduction in monocyte-platelet aggregates observed.
Week 12: Further decrease in monocyte-platelet aggregates.
Three months: Duration of the pilot study treatment and assessments.
Health Landscape
This study aligns with broader efforts at Vanderbilt Health to redefine the therapeutic potential of SGLT2 inhibitors. It marks a shift from focusing exclusively on glucose regulation toward understanding how these drugs mitigate the systemic inflammation inherent in metabolic disease.
If you have prediabetes, discuss your current cardiovascular risk profile with your doctor during your next visit. This study highlights the importance of addressing inflammation as part of a comprehensive strategy to maintain heart health.
The takeaway
This study highlights a potential new benefit for SGLT2 inhibitors in curbing inflammation associated with metabolic conditions. Talk to your healthcare provider about whether your current treatment plan addresses both blood sugar and markers of systemic inflammation.
What happens next
Researchers have initiated a randomized, placebo-controlled trial with 74 participants to further analyze these inflammatory changes, including sampling adipose tissue.
Further reading
For more on managing metabolic health, visit our Diabetes section.
Live Poll
Should medical research prioritize finding new uses for existing drugs to help treat chronic health conditions?
